Oltra, Sara S.
Colomo, Sara
Sin, Laura
Pérez-López, María
Lázaro, Sara
Molina-Crespo, Angela
Choi, Kyoung-Han
Ros-Pardo, David
Martínez, Lidia
Morales, Saleta
González-Paramos, Cristina
Orantes, Alba
Soriano, Mario
Hernández, Alberto
Lluch, Ana http://orcid.org/0000-0003-2766-407X
Rojo, Federico
Albanell, Joan
Gómez-Puertas, Paulino
Ko, Jae-Kyun
Sarrió, David
Moreno-Bueno, Gema http://orcid.org/0000-0002-5030-6687
Funding for this research was provided by:
AECC Scientific foundation POSTD20028OLTR
Article History
Received: 27 July 2022
Revised: 17 February 2023
Accepted: 21 February 2023
First Online: 11 March 2023
Competing interests
: AL declares advisory boards and consulting fees from Novartis, Pfizer, Genentech, Roche, Eisai, Celgene; Research funding-clinical trials for institution from Novartis, Pfizer, Roche/Genentech, Eisai, Celgene, Roche Pharma AG, AstraZeneca, Merck, PharmaMar, Boehringer Ingelheim, Amgen, GlaxoSmithKline, Pierre Fabre. FR has received research grants from Roche; Consulting/advisory fees from BMS, MSD, AstraZeneca, Janssen, Roche/Genentech, Novartis, Eli Lilly, and Daiichi Sankyo. JA has received consulting or advisory role fees from Roche, Pfizer, Amgen, MSD, Lilly and Daiichi-Sankyo; research funding or grant support trials by Roche, Pfizer, Amgen, MSD, Lilly, Daiichi-Sankyo; and travel and accommodation support from Roche, Pfizer, Amgen, MSD, Lilly and Daiichi-Sankyo. The rest of authors declare no conflict of interest.